Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03611387
Other study ID # CCPMOH2018-China-4
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 1, 2018
Est. completion date December 31, 2019

Study information

Verified date July 2018
Source Sun Yat-sen University
Contact Jing Li, M.D
Phone +86-20-87330341
Email Reviewborad_SYsU@163.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The Tomey CASIA (Tomey Corporation, Nagoya, Japan) is a novel rapid imaging device that captures high-quality imaging of the entire anterior chamber of the eye over detailed imaging of a single section. In this prospective study, we want to investigate and compare the anatomical structure of the drainage angle of the eye in patients with different types glaucoma using Tomey machine. This study gives us a better understanding of the predictability, validity and accuracy of Tomey machine in the diagnosis of different types of glaucoma. Moreover, the data collected here will be used to create an artificial intelligence (AI) platform to screen certain type of glaucoma.


Description:

Patients ≥18 years old from ophthalmic clinics with or without glaucoma were enrolled to this respective observational clinical study. However, patients with any history of eye surgery (except cataract surgery) including laser procedure were excluded. The investigators will review patients' medical chart and update any medical history in your medical record. If new scans are needed, investigators will do them at the time of patients' current visit and it will require about 30 mins. CASIA SS-OCT (CASIA 2) is a non-contact scan of the front of the eye with higher resolution and provides deeper, wider and three- dimensional views. It is the newest scan machine. It is not FDA-approved but is approved in many other countries including Japan for patient use. We may perform the scan in the light and dark condition. We may also perform the routine scan to capture images of the anterior part of the eye for comparison purpose. The results of the scanned data will be among patients' medical records. Age, sex and ethnicity within your medical records will also be used for the analysis.


Recruitment information / eligibility

Status Recruiting
Enrollment 1500
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient with or without glaucoma

Exclusion Criteria:

- Patients with any history of eye surgery (except cataract surgery) including laser procedure.

- Age < =18 years

Study Design


Intervention

Device:
CASIA 2 OCT
Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods

Locations

Country Name City State
China Zhognshan Ophthalmic Center, Sun Yat-sen University Guangzhou Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Sun Yat-sen University University of California

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The accuracy of the CASIA 2 OCT To compare the clinical applicability, accuracy, and validity of the CASIA 2 OCT (Tomey, Nagoya, Japan) in the assessment of anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods. baseline
Primary The sensitivity and specificity of the AI To create an AI program to reliably screen patients with certain type of glaucoma (such as primary angle closure glaucoma, PACG) using images from CASIA 2 OCT. To test the sensitivity and specificity of the AI program to screen patients with glaucoma using images from CASIA 2 OCT. Another database comprised of CASIA 2 OCT images will be created and used to test the AI program. The diagnosis based on the AI program will be compared with diagnosis from glaucoma specialist. baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05414994 - Assessment of the Ocular Microbiome in Health and Disease
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT05494242 - Single Superior ILM/ERM Flap for the FTMH. N/A
Terminated NCT05494229 - Autologous Blood for Full-thickness Macular Hole N/A
Completed NCT04982484 - Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
Completed NCT04683055 - Phaco-Trabeculotomy Vs Phaco-Trabeculectomy N/A
Recruiting NCT06367517 - Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Completed NCT03766737 - Validation of the Utility of an Intelligent Visual Acuity Diagnostic System for Children N/A
Recruiting NCT04460001 - Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO) Phase 2/Phase 3
Completed NCT04917562 - Refractive Transepithelial Photo-keratectomy (T-PKR) in High Myopia
Completed NCT04771039 - Ocular Manifestations of Inflammatory Bowel Disease
Completed NCT03492242 - Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
Withdrawn NCT04579458 - Assessment of COVID-19 in Tearfilm
Completed NCT03855462 - Evaluating Medium-chain Triglycerides as a Temporary Intraocular Tamponading Agent for Retinal Detachment N/A
Recruiting NCT06293586 - Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery N/A
Recruiting NCT06102265 - Effect Of Reusing the Operative Supplies On Cataract Surgery and Climate Change
Completed NCT03499145 - Validation of the Utility of Ophthalmology Intelligent Diagnostic System